A 14-day, open-label study assessed the effects of tacrolimus ointment 0.1% twice daily in 24 patients with perianal eczema. The eczema was assessed by using a modified SCORing Atopic Dermatitis (SCORAD) index. Sixteen patients completed the study. The modified SCORAD index decreased significantly after 2 weeks (P < 0.001) as did both intensity of eczema and erythema. Side effects were limited to a mild burning sensation at the start of treatment (Schauber, J. et al. Br J Dermatol 2009, 161(6): 1384).